Literature DB >> 26961148

Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development.

A Yver1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26961148     DOI： 10.1093/annonc/mdw129

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  25 in total

Review 1.  Advances of small molecule targeting of kinases.

Authors:  Norbert Berndt; Rezaul M Karim; Ernst Schönbrunn
Journal:  Curr Opin Chem Biol       Date:  2017-07-18       Impact factor: 8.822

Review 2.  Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.

Authors:  Simon Vyse; Annie Howitt; Paul H Huang
Journal:  J Mol Biol       Date:  2017-05-03       Impact factor: 5.469

Review 3.  Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.

Authors:  Marshall L Spiegel; Jonathan W Goldman; Brian R Wolf; Danielle J Nameth; Tristan R Grogan; Aaron E Lisberg; Deborah J L Wong; Blanca A Ledezma; Melody A Mendenhall; Scott J Genshaft; Antonio J Gutierrez; Fereidoun Abtin; W Dean Wallace; Carlos R Adame; Jordan R McKenzie; Phillip A Abarca; Alice J Li; Jennifer L Strunck; Sina Famenini; James M Carroll; D Andrew Tucker; Lauren M Sauer; Nima M Moghadam; David A Elashoff; Christina D Abaya; Meghan B Brennan; Edward B Garon
Journal:  Cancer       Date:  2017-11-10       Impact factor: 6.860

4.  Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer.

Authors:  Chong-Kin Liam
Journal:  Transl Lung Cancer Res       Date:  2017-12

5.  Capilliposide from Lysimachia capillipes inhibits AKT activation and restores gefitinib sensitivity in human non-small cell lung cancer cells with acquired gefitinib resistance.

Authors:  Shi-Rong Zhang; Ya-Si Xu; Er Jin; Lu-Cheng Zhu; Bing Xia; Xu-Feng Chen; Fan-Zhu Li; Sheng-Lin Ma
Journal:  Acta Pharmacol Sin       Date:  2016-11-14       Impact factor: 6.150

Review 6.  Recent Advances in Selective and Irreversible Covalent Ligand Development and Validation.

Authors:  Tinghu Zhang; John M Hatcher; Mingxing Teng; Nathanael S Gray; Milka Kostic
Journal:  Cell Chem Biol       Date:  2019-10-17       Impact factor: 8.116

Review 7.  Drug development in the era of precision medicine.

Authors:  Sarah A Dugger; Adam Platt; David B Goldstein
Journal:  Nat Rev Drug Discov       Date:  2017-12-08       Impact factor: 84.694

Review 8.  Targeting EGFR in Lung Cancer: Current Standards and Developments.

Authors:  Asunción Díaz-Serrano; Pablo Gella; Elisabeth Jiménez; Jon Zugazagoitia; Luis Paz-Ares Rodríguez
Journal:  Drugs       Date:  2018-06       Impact factor: 9.546

9.  Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.

Authors:  Wenyuan Xiong; Manja Friese-Hamim; Andreas Johne; Christopher Stroh; Manfred Klevesath; Gerald S Falchook; David S Hong; Pascal Girard; Samer El Bawab
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-05-01

Review 10.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.

Authors:  Lei Zhong; Yueshan Li; Liang Xiong; Wenjing Wang; Ming Wu; Ting Yuan; Wei Yang; Chenyu Tian; Zhuang Miao; Tianqi Wang; Shengyong Yang
Journal:  Signal Transduct Target Ther       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.